Lipum AB has published the interim report for period July-September 2022. Below is a short summary, a complete report (only in Swedish) is available on the company's website. CEO Einar Pontén comments: “In early November, we were able to report that our Phase 1 clinical trial had started. Preparations for this were a major activity [...]
Lipum AB (publ) announces that the Phase 1 clinical study with the drug candidate SOL-116 has started and is progressing according to plan. To date, a first dose group of eight healthy volunteers have received a dose, with two of the volunteers receiving placebo. The drug candidate SOL-116 is a fully humanised antibody that, through [...]
Press release: Umeå, October 19, 2022. Lipum AB (publ) (“Lipum” or the “Company”) announces that the directed share issue of approximately SEK 39 million before deduction of transaction costs (the “Directed Share Issue”) has been fully subscribed.The Board of Directors of Lipum resolved on September 22, 2022, subject to the approval by the General Meeting, on [...]
Press release: Umeå, October 12, 2022. The Extraordinary General Meeting (the “EGM”) in Lipum AB (publ), corporate identity number 556813-5999 (”Lipum” or the “Company”), today resolved to approve the Board of Directors’ resolution on a directed share issue of 2,601,732 new shares.The EGM resolved to approve the Board of Directors’ previous resolution on September 22, [...]
Press release: Umeå, 27 September, 2022. Lipum AB (publ) announces today that the CTA (clinical trial application) for the drug candidate SOL-116 has been approved by the regulatory authorities in The Netherlands.The study that includes healthy volunteers and patients with rheumatoid arthritis will be carried out at QPS BV facility in Groningen, Netherlands. The study [...]
Press release: Umeå, September 22, 2022. The Board of Directors of Lipum AB (publ) (“Lipum” or the “Company”) has resolved on a directed issue of 2,601,732 shares at a subscription price of SEK 14.99 per share to Flerie Invest AB and certain other existing and new investors with pronounced long-term interests in the Company (the [...]
News: Umeå, 9 August 2022. Lipum (publ), a biopharmaceutical company focused on chronic inflammatory diseases, today announced its participation in the following upcoming conferences.LSX Nordic, Copenhagen, Denmark, 6-7 September Biostock Investerarevent, digital, 14 September Nordic Life Science Days, Malmö, Sweden, 28-29 September Bio-Europe, Leipzig, Germany, 24-26 October Redeye Life Science Day, Stockholm, Sweden, 24 [...]
Press release: Umeå, 27 July, 2022. Lipum AB has published the interim report for period January to June 2022. Below is a short summary, a complete report (only in Swedish) is available on the company's website (https://lipum.se/finansiella-rapporter/).CEO Einar Pontén comments: “Through long-term and systematic work, we are now almost ready to start clinical trials. We have [...]
News: Umeå, 8 July, 2022. Lipum (publ) is preparing for the start of its first in human phase 1 clinical trial and the team is now strengthened with Dr. Helena Bergström that has been recruited as chief medical officer (CMO).Dr. Helena Bergström is an experienced clinician that previously also has been involved in research of [...]
Press release: Umeå, 17 June 2022. Lipum (publ) reports that the GLP toxicology- and safety program on the candidate drug (SOL-116) has been completed. The drug antibody was well tolerated also in high doses and the results supports submission of a Clinical Trial Application (CTA).The non-clinical program for toxicology- and safety studies of Lipum’s candidate [...]